Patients with advanced prostate cancer taking Bristol-Myers Squibb's (BMY) melanoma treatment Yervoy lived 11.2 months on average, versus 10 months on placebo, not enough of a difference to constitute statistical significance, data shows.
The 800 patient trial enrolled individuals who had previously received chemotherapy and who had failed to benefit from testosterone-lowering drugs.
From the study, it appears Yervoy's best chance (at least for prostate cancer) may be in patients whose disease has not yet spread. The drug is being tested specifically for such an indication in a separate Phase 3 trial which should wrap in 2015, Reuters says.
Sales of Yervoy grew 44% to $233M in Q2.